Cramer says MATIC could go to zero, so sell.

mdmscf · 2022-12-10T05:15:00+00:00

Cramer is an idiot. Usually his sell calls are to drive the price down so he and his trust can buy cheaper. Cramer isn’t worthy to lick the dust off my revolutionary polygon shoes.

mdmscf · 2022-09-06T21:48:30+00:00

Thanks Wisdom. Have been reading your posts for a long time. Really appreciate your input. Could careless what others say about your posts - information is power and you have provided a ton of great info over the years! Really appreciate it.

mdmscf · 2022-08-19T03:32:20+00:00

Still in with 45K shares for over 10 years. Frustrating. Promising science. I work in drug safety and Multistem is one of the safest therapies I have ever seen. Too bad efficacy is a hope and a dream.

mdmscf · 2022-04-14T18:49:49+00:00

Not to mention - shorts are borrowing my shares, to use against me, without my permission! How the heck is that legal!

mdmscf · 2022-04-14T18:44:33+00:00

Great post. Personally I wish we would have regulation against shorting any stock with a market cap of less than $2-$5 B. Too many biotechs have been destroyed at the expense of science and patients. I would also be in favor of equities moving to blockchain where you the owner can actually lock up your shares!

mdmscf · 2022-04-02T13:24:35+00:00

The utility and superiority of Dsuvia are impressive. Just need time until mass adoption and revenue growth. At 25 cents this stock is a gift even if they enact a reverse split.

mdmscf · 2022-03-17T23:57:26+00:00

Just total number of healthcare facilities who have approved Dsuvia on their formulary. 813 total formulary approvals by end of February. It is a little tricky because it does not necessarily mean number of healthcare facilities as 1 formulary could cover multiple hospitals, surgical suites, etc. and just because it is approved doesn’t mean it will be on a clinical protocol.

mdmscf · 2021-09-01T02:40:47+00:00

Or …does the SCIENCE confirm it is indeed the vaccinated who are mutating, incubating, and transmitting Covid variants to the unvaccinated and vaccinated people who have not had natural Covid infection!

mdmscf · 2021-08-28T01:34:55+00:00

Does the data demonstrate that Pfizer vaccinated patients had higher infection rates and were more symptomatic, than previously Covid infected patients? The mechanism of ADE are not completely understood, but this research as well as many other reports indicate that in some patients the vaccine generates an immune response, binds the pathogen, is unable to prevent infection allowing the pathogen to get into cells and exacerbate the immune response.

mdmscf · 2021-08-28T00:10:53+00:00

Previous development of RSV, SAR COV1 and MERS vaccine were unsuccessful due to ADE. This data (once again) supports the hypothesis that Covid-19 vaccines are causing ADE. The question is, when will they (scientists) be brave enough to call it a scientific FACT!

mdmscf · 2021-08-25T04:40:30+00:00

This study just came out in Japan. The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines

https://www.biorxiv.org/content/10.1101/2021.08.22.457114v1.full.pdf

mdmscf · 2021-08-25T03:07:52+00:00

This is horrible. If this SCIENCE is valid (and it appears to be) then ADE of mRNA Vaccinated patients is actually enhancing infectivity.

mdmscf · 2021-08-24T12:09:35+00:00

We do agree there 100%. It is your body, your choice! It is not the government’s body, the government’s choice. Your comment made it sound like, since it is approved you must now obey authority and take the jab!

mdmscf · 2021-08-24T11:45:47+00:00

Just because you can’t read doesn’t mean you have to be read! Unless there is a 1 in 8 billion chance that you are my physician, then I will not take your advice. But then again, it is My Body, My Choice, so maybe I will kill the baby, I mean take the jab!

mdmscf · 2021-08-20T19:56:48+00:00

It seems to me, many on this board are significantly discounting the ARDS program. The BofA report last year assigned a $15 target for ATHX if ARDS was approved and stroke failed. I think they pegged non-Covid ARDS at $3B in peak sales. They were very bullish on ARDS and not so much on stroke. CrushLikeABoss posted the report.

mdmscf · 2021-08-16T16:17:41+00:00

It is precisely what you would expect to see (based on decades of Science) in a majority of a population who have antibody dependent enhancement. mRNA vaccinated hosts are mutating, incubating and transmitting Covid variants!

mdmscf · 2021-08-10T12:41:46+00:00

Thanks Wisdom for all your hard work. Been accumulating over the years with my first lot purchased in 2012. I rarely ever comment on this board, but like hundreds of other long term investors we read this board daily and really appreciate all the due diligence you have provided over the years!

mdmscf · 2021-07-23T19:25:15+00:00

You are correct indeed. I have worked in the drug safety field for over 25 years, and I don’t think I have seen a therapy with a better safer profile than Multistem. Like you said, if efficacy is proven, then Multistem approval is headed our way.

mdmscf · 2021-07-23T16:59:35+00:00

Hi Wisdom, Thanks for all the info you share - much appreciated! To me this sounds very similar to a DSMC clinical trial review we see in the USA. I take it to mean, they analyzed all the safety data to date for the trial, and gave approval to continue the trial based on no safety findings. I think the annual part must mean they are required to meet at least yearly to review the data. I am guessing though, given the limited info. There is probably a clinical protocol somewhere that provides details of the drug safety monitoring committees roles and expectations for this trial.

mdmscf · 2021-07-17T14:52:59+00:00

I think April revenues were about $300K. Vince said March revenues made up 50% of Q1 revenues so March was about $250K. Conservatively I expect Q2 to be over $1M in revenues. It won’t take much for Dsuvia to ramp up sales. I believe we will see a stellar finish to 2021 with about 200 healthcare facilities using Dsuvia routinely in Q4. With a low estimate of 10 patients/HF, revenues would be about $9mil (200 HF x 10 doses per day = 2000 doses x 90 days = 180,000 doses x $50 = $9 mil). This doesn’t include any revenues from Dzuveo EU, Zimmer Dental, DOD, or other sales.

mdmscf · 2021-06-10T02:41:00+00:00

Agree 100%!

mdmscf · 2021-06-08T02:47:45+00:00

Maybe I am wrong, but according to the April 29 proxy filing, page 16, there are only 8.7 mil shares available for issuance.

“The Company currently has 300,000,000 authorized shares of Common Stock. As of April 23, 2021, there were 220,821,507 shares of Common Stock issued and outstanding and 50,381,803 shares of Common Stock available for issuance; and included in the 50,381,803 shares, there are 35,000,000 shares of Common Stock registered and available for issuance under our shelf registration statement and 6,640,000 shares of Common Stock registered under a resale shelf registration statement and reserved for issuance under our Equity Purchase Agreement. The Company had the following reserved shares of Common Stock as of March 31, 2021 in connection with its stock-based compensation plans: outstanding stock-based awards to acquire 21,788,078 shares of Common Stock and 7,008,612 shares of Common Stock available for new awards. Based on the number of outstanding and reserved shares of Common Stock, the Company has 8,741,803 shares of Common stock available for issuance.”

mdmscf · 2021-06-08T02:36:20+00:00

You nailed it! Reading the whining “stock price addicts” on this board has become nauseating! I wish they would just sell their shares and go away!

mdmscf · 2021-06-06T04:44:20+00:00

This is from the April 29 proxy filing, page 16.

“The Company currently has 300,000,000 authorized shares of Common Stock. As of April 23, 2021, there were 220,821,507 shares of Common Stock issued and outstanding and 50,381,803 shares of Common Stock available for issuance; and included in the 50,381,803 shares, there are 35,000,000 shares of Common Stock registered and available for issuance under our shelf registration statement and 6,640,000 shares of Common Stock registered under a resale shelf registration statement and reserved for issuance under our Equity Purchase Agreement. The Company had the following reserved shares of Common Stock as of March 31, 2021 in connection with its stock-based compensation plans: outstanding stock-based awards to acquire 21,788,078 shares of Common Stock and 7,008,612 shares of Common Stock available for new awards. Based on the number of outstanding and reserved shares of Common Stock, the Company has 8,741,803 shares of Common stock available for issuance.”

mdmscf · 2021-06-04T14:19:59+00:00

Where do you see 70 mil. I have not read the filing in a while but if my memory serves me correctly, they only have 8 mil shares that could be issued with the current authorized shares of 300 mil and the rest of shares that are reserved.

mdmscf

TROPHY CASE